Back to Browse Journals » Neurobehavioral HIV Medicine » Volume 3

Anti-HIV-1 drug toxicity and management strategies

Authors Sharma B

Published 28 April 2011 Volume 2011:3 Pages 27—40


Review by Single-blind

Peer reviewer comments 2

Bechan Sharma
Department of Biochemistry, University of Allahabad, Allahabad, India

Abstract: Antihuman immunodeficiency virus type 1 (anti-HIV-1) medications have helped millions of HIV-1-infected people lead longer and healthier lives. The goal of HIV-1 treatment is to reduce the number of virions in the body of infected individuals and to prevent rapid destruction of CD4+ T-lymphocyte cells, thus protecting the immune system. Most of the anti-HIV-1 drugs in practice are designed using viral reverse transcriptase (HIV-1RT), protease, and integrase as targets. These drugs that inhibit the activities of HIV-1RT, viral protease, and integrase are therefore known as anti-HIV-1RT, antiprotease, and anti-integrase molecules, respectively. The US Food and Drug Administration has approved 22 anti-HIV-1/acquired immunodeficiency syndrome (AIDS) drugs for clinical use by HIV-1-infected individuals and AIDS patients. Among the drugs, most of the nucleoside analogs (excluding two isomers of 3TC, (-)3TC and (+)3TC, which are shown to be less toxic in cell culture) exhibit clinical complications that pose a threat to chemotherapy. The toxicity of these molecules arises due to their negative impact on the activities of human mitochondrial chromosomal DNA polymerases (a, d, ß, and e) in general and DNA polymerase γ in particular. Other anti-HIV-1 regimens are also reported to cause toxicity. The range of toxicity extends from mild to life-threatening levels. The prolonged use of zidovudine (3′-azido-3′-deoxythymidine [AZT] or Retrovir), which was first approved in 1987 as a nucleoside analog reverse transcriptase inhibitor, has been reported to cause severe hematologic toxicity, including severe anemia, granulocytopenia, and symptomatic myopathy. Many other drugs that are often used in combination with AZT have similar toxicities. The newer antiretrovirals (ARVs), such as 2′,3′-dideoxycytidine, 2′,3′-dideoxyinosine, and 2′,3′-dideoxy-2′,3′-didehydrothymidine, which exhibit analogous mechanisms of action and similar toxicities to AZT, have not been studied extensively. Acyclovir and gancyclovir can cause severe nausea and vomiting. Some of these ARVs when taken during pregnancy may generate teratogenic effects. Similarly, use of antiproteases in highly active ARV therapy causes hepatotoxicity, which poses a severe risk to the patients. In addition, application of fusion inhibitors and anti-integrases induces strong side effects in HIV-1-infected or AIDS patients. The present review illustrates a comprehensive analysis of the existing literature on the toxicity of anti-HIV-1/AIDS drugs, their mechanisms of action, and possible management strategies to combat this problem.

Keywords: HIV-1, AIDS, anti-HIV-1RT drugs, antiproteases, anti-integrases, fusion inhibitors, dosage, toxicity, management

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Low temperature induced alterations in certain biochemical constituents of 5th instar larvae of Philosamia ricini (Lepidoptera: Satunidae)

Anita Singh, Ratnesh Kr Sharma, Bechan Sharma

Open Access Insect Physiology 2010, 2:11-16

Published Date: 7 July 2010

Readers of this article also read:

Adjuvant corneal crosslinking to prevent hyperopic LASIK regression

Aslanides IM, Mukherjee AN

Clinical Ophthalmology 2013, 7:637-641

Published Date: 31 March 2013

Nucleocytoplasmic transport blockage by SV40 peptide-modified gold nanoparticles induces cellular autophagy

Tsai TL, Hou CC, Wang HC, Yang ZS, Yeh CS, Shieh DB, Su WC

International Journal of Nanomedicine 2012, 7:5215-5234

Published Date: 8 October 2012

The neuro-ophthalmology of HIV-AIDS review of Neurobehavioral HIV Medicine

Sudhakar P, Kedar S, Berger JR

Neurobehavioral HIV Medicine 2012, 4:99-111

Published Date: 18 September 2012

Simple filter microchip for rapid separation of plasma and viruses from whole blood

Wang SQ, Sarenac D, Chen MH, Huang SH, Giguel FF, Kuritzkes DR, Demirci U

International Journal of Nanomedicine 2012, 7:5019-5028

Published Date: 17 September 2012

Development of neurocognitive disorders in HIV/AIDS

Brandon C Dennis, Sidney A Houff, Dong Y Han, et al

Neurobehavioral HIV Medicine 2011, 3:9-18

Published Date: 10 March 2011

Liver transplantation in Egypt from West to East

Galal H El-Gazzaz, Azza H El-Elemi

Transplant Research and Risk Management 2010, 2:41-46

Published Date: 7 April 2010

Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus

R Pradeep Kumar, D Sujatha, TS Mohamed Saleem, C Madhusudhana Chetty, D Ranganayakulu

Journal of Experimental Pharmacology 2010, 2:29-36

Published Date: 10 February 2010